Your browser doesn't support javascript.
loading
Addendum to British Society for Haematology Guideline for the management of mantle cell lymphoma, 2018 (Br. J. Haematol. 2018; 182: 46-62): Risk assessment of potential CAR T candidates receiving a covalent Bruton tyrosine kinase inhibitor for relapsed/refractory disease.
O'Reilly, Maeve A; Sanderson, Robin; Wilson, William; Iyengar, Sunil; Lambert, Jonathan; McCulloch, Rory; Eyre, Toby A.
Affiliation
  • O'Reilly MA; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
  • Sanderson R; Department of Haematology, Kings college Hospital, London, UK.
  • Wilson W; UCL Cancer Trials Centre, University College London, London, UK.
  • Iyengar S; Department of Haematology, Royal Marsden Hospital, London, UK.
  • Lambert J; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
  • McCulloch R; Department of Haematology, Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK.
  • Eyre TA; Department of Haematology, Oxford University NHS Trust, Oxford, UK.
Br J Haematol ; 199(1): 40-44, 2022 10.
Article in En | MEDLINE | ID: mdl-35894253
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Main subject: Lymphoma, Mantle-Cell / Receptors, Chimeric Antigen / Hematology Type of study: Etiology_studies / Guideline / Risk_factors_studies Limits: Adult / Humans Language: En Journal: Br J Haematol Year: 2022 Type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Main subject: Lymphoma, Mantle-Cell / Receptors, Chimeric Antigen / Hematology Type of study: Etiology_studies / Guideline / Risk_factors_studies Limits: Adult / Humans Language: En Journal: Br J Haematol Year: 2022 Type: Article